The frequency of ARID1A variations in ovarian clear cell carcinomas is up to 60% in the US, Canada, and Japan, indicating that ARID1A deficiency may be a potential biomarker for precision medicine of ovarian cancer (Takahashi et al. 2021). This evidence concerns the gene ARID1A and ovarian clear cell cancer.